Oxigene will price $20 million public offering of common-share units

Deal conducted by H.C. Wainwright to finance working capital, research

By Devika Patel

Knoxville, Tenn., Aug. 8 - Oxigene Inc. plans to price a public offering of units for up to $20 million, according to a Form S-1 filed Thursday with the Securities and Exchange Commission. H.C. Wainwright & Co., LLC is the agent for the offering.

The company will sell units of common shares and warrants.

Proceeds will be used for working capital, research and development activities and general corporate purposes, including continuing commercialization and research and development efforts for Zybrestat and OXi4503.

Oxigene is a pharmaceutical company located in South San Francisco, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.